Why the hip is harder to inject than most joints

The anterior hip joint space sits 4–8 cm beneath the skin — roughly three to four times deeper than the accessible medial compartment of the knee. That depth alone raises the technical bar for any injection, but the neighbourhood the needle must traverse makes the hip categorically different from most other joints.

Packed around the anterior capsule are three major neurovascular structures with little tolerance for error: the femoral artery lies approximately 1.9 cm medial to the capsule, the femoral vein approximately 1.7 cm medial, and the femoral nerve approximately 2.3 cm lateral. More problematic still is the lateral circumflex femoral artery (LCFA), which courses directly over the anterior capsule — but at a position that varies between patients and cannot be inferred from any bony or palpable surface landmark. No landmark technique can map it before the needle moves.

The practical consequence shows in the literature. Hoeber et al.'s 2016 systematic review and meta-analysis, published in the British Journal of Sports Medicine and cited 119 times, found that landmark-guided hip injections achieved accurate intra-articular placement in only 72% of cases (95% CI 56–85%). One in four blind injections misses the joint entirely, delivering the injectate into surrounding soft tissue rather than the capsular recess.

For most injectables, a misplaced dose wastes the treatment. For ChondroFiller™ — which polymerises within 3–5 minutes at body temperature — the consequences are permanent: collagen deposited outside the capsule cannot contribute to cartilage repair and cannot be retrieved once it has set. Precision is not a procedural preference; it is a clinical requirement.

How ChondroFiller works once it is inside the hip joint

ChondroFiller™ is not a drug, a cell therapy, or a lubricant. Manufactured by Meidrix Biomedicals GmbH and CE-marked as a Class III medical device, it is an acellular, injectable Type I collagen hydrogel — a purely structural scaffold containing no living cells, growth factors, or pharmaceutical agents of any kind.

Once inside the joint at body temperature, the liquid polymerises into a soft, three-dimensional matrix that sits directly over the cartilage defect. The mechanism is acellular matrix-induced chondrogenesis (ACIC): the scaffold creates a chemotactic environment that draws the patient's own mesenchymal progenitor cells in from the surrounding synovium and subchondral bone. Those recruited cells progressively populate the matrix and begin laying down fibrocartilage-like repair tissue. Over the following three to six months, the collagen scaffold gradually resorbs as that endogenous repair tissue matures — promoting the body's own repair processes rather than supplying a synthetic substitute.

The practical implication of this biology is straightforward: a scaffold deposited outside the focal defect cannot attract cells to the right location, cannot reposition itself once gelled, and cannot promote repair where it is needed. Because polymerisation takes approximately three to five minutes at body temperature, the injection must land precisely on — or immediately adjacent to — the cartilage lesion before that window closes. It is this irreversibility that makes real-time ultrasound guidance not a procedural refinement but a biological necessity.

Which hip patients are suitable for this pathway

Not every patient with hip pain is a candidate for this pathway. ChondroFiller is indicated for focal, contained cartilage loss — specifically ICRS Grade III or IV defects measuring approximately 2–6 cm² — where the surrounding articular surface remains healthy. The two presentations that most commonly meet these criteria are FAI-related acetabular damage, where abnormal femoroacetabular contact progressively erodes a discrete cartilage area, and post-traumatic focal loss following hip dislocation or impact.

Published data make the exclusion criteria equally clear. A cohort study by Mazek et al. (2021, n=26) found that patients with pre-existing diffuse osteoarthritis — Tönnis Grade 2 or 3 — did not achieve meaningful benefit from ChondroFiller in the hip. Diffuse degeneration provides neither the localised defect geometry nor the intact surrounding environment the scaffold requires. This is why an MRI of the hip is required before any appointment is confirmed: it maps defect size, morphology, and the condition of the surrounding joint, establishing whether the procedure is likely to help rather than simply adding a step to the process.

For borderline cases where it is unclear whether the hip joint itself is the dominant pain source, an ultrasound-guided local anaesthetic injection can serve a useful diagnostic role. A 2024 cohort study of 119 FAI patients found that those achieving a ≥8.5-point VAS improvement after such an injection went on to achieve substantial clinical benefit in 70.6% of cases at two-year follow-up — confirming the joint as the pain generator before committing to further treatment.

Lincolnshire Hip also offers Arthrosamid for patients whose MRI findings or OA severity places them outside the ChondroFiller indication. The distinction is mechanistic: Arthrosamid is a permanent polyacrylamide hydrogel that provides joint cushioning without any regenerative intent, whereas ChondroFiller is a biodegradable scaffold aimed specifically at promoting endogenous tissue repair within a focal defect. The two are not interchangeable, and the choice between them turns on defect morphology, OA severity, and clinical assessment.

How ultrasound guidance achieves accurate hip joint access

The appointment begins on an outpatient couch. Before any needle is prepared, the clinician places a low-frequency ultrasound transducer over the anterior hip and activates Colour Doppler — a mode that displays moving blood as coloured signals on screen. This maps the femoral artery, the femoral vein, and the lateral circumflex femoral artery (LCFA), whose course over the anterior capsule varies between patients and cannot be predicted from surface landmarks. A safe needle corridor is identified only once those structures are located.

With that vascular map established, a long spinal needle is tracked in real time — in-plane with the transducer — through the overlying soft tissue and iliofemoral ligament toward the synovial recess at the femoral head-neck junction. The clinician watches the needle tip on screen throughout. Once the tip is confirmed inside the capsular recess, ChondroFiller is delivered slowly, and the spread of the collagen liquid within the joint is visible on screen before it sets.

This live visualisation is the decisive advantage over fluoroscopy. Fluoroscopy uses ionising radiation, typically requires contrast medium to confirm joint entry, and cannot display vessels or nerves at all. Ultrasound shows all of these simultaneously, imposes no radiation dose, and requires no dedicated imaging suite or theatre booking.

A 2025 study of 276 hip arthrograms using a lateral short-axis ultrasound approach reported 99.3% adequate intra-articular placement with zero vascular complications. The lateral approach was deliberate: bypassing the anterior route specifically reduces LCFA injury risk — an advantage that landmark-guided or fluoroscopic technique cannot reliably replicate.

What the outcome evidence actually shows

Calibrating expectations honestly means separating three layers of evidence: data from the broader ChondroFiller programme, outcomes from hip-specific arthroscopic use, and direct results for ultrasound-guided injectable delivery in the hip — where the published record is currently thinner.

The hip-specific patient-facing anchor is an approximately 30-point improvement in modified Harris Hip Score (mHHS). The mHHS runs from 0 to 100; a shift of around 8–10 points is typically the minimum considered clinically meaningful, making a 30-point gain a substantial functional change rather than a marginal one.

Arthroscopic hip data from Mazek et al. (2021, n=26 FAI patients) show 17 of 21 patients achieving good or excellent outcomes at 3–5 years — an 81% rate. Those patients received ChondroFiller by arthroscopic implantation, not ultrasound-guided injection, and presenting those figures as if they described the current outpatient pathway would misrepresent how the evidence was collected.

Across the broader ChondroFiller evidence base, MOCART scores — a 0–100 MRI-based scale for cartilage repair tissue quality — fall in the range of 70–87, where results above 70 indicate substantial defect filling. A formal complaint rate of approximately 0.06% reflects a consistently strong safety profile across the programme.

Direct peer-reviewed outcomes for ChondroFiller as an ultrasound-guided injectable specifically in the hip remain limited, and patients should weigh that gap. What the current evidence does establish is a well-characterised biological mechanism, independently verified delivery accuracy under ultrasound, and outcome data from the same joint via a comparable implantation route. Pre-injection MRI — confirming a focal defect and excluding Tönnis Grade 2–3 disease — is the strongest evidence-based safeguard for ensuring a patient belongs to the population where benefit has actually been demonstrated, and it is also what separates the injectable pathway from the arthroscopic setting in which most outcome data were gathered.

The ChondroFiller pathway at Lincolnshire Hip

Access to ChondroFiller at Lincolnshire Hip follows a straightforward outpatient pathway. Consultations are held locally — in Grantham and Sleaford — under Professor Paul Lee, a hip specialist who leads the full service from initial assessment through to injection day and follow-up.

Because ChondroFiller is not funded by the NHS for hip indications, patients attend on a self-pay basis or through private medical insurance; it is worth confirming cover in advance. The pre-treatment pathway includes a clinical consultation and, where not already available, an MRI of the hip to verify defect size and confirm suitability — the same imaging that identifies the focal cartilage lesions where this treatment is most likely to help.

The ultrasound-guided injectable protocol used at Lincolnshire Hip reflects the approach first introduced to the UK by the affiliated London Cartilage Clinic — the first centre in the country to offer ChondroFiller as an intra-articular injection. That clinical lineage matters: the technique has been refined prospectively, with outcome data collected across a growing patient cohort.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral for hip assessment.